Literature DB >> 19664621

Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease.

Uzma Chaudhry1, Hean Zhuang, Sylvain Doré.   

Abstract

Nonsteroidal anti-inflammatory drugs, such as cyclooxygenase (COX)-2 inhibitors, have been unsuccessful in slowing or reversing Alzheimer's disease (AD). Thus, understanding the expression patterns of the downstream effectors for the regulation of prostaglandin synthesis may be important for understanding the pathological processes involved in AD and formulating more effective pharmacotherapeutics for this disease. In this study, we used immunofluorescence, immunohistochemistry, and Western blot analysis to compare patterns of microsomal prostaglandin E synthase (mPGES)-2 expression in the middle frontal gyrus (MFG) of AD patients and age-matched controls. In control human brain sections, mPGES-2 immunoreactivity was observed in neurons, activated microglia, and endothelium, but not in resting microglia, astrocytes, or smooth muscle cells. Microsomal PGES-2 immunoreactivity was particularly elevated in the pyramidal neurons of brains from three of five sporadic and four of five familial AD patients compared with four of five age-matched control brains that showed minimal immunoreactivity. In contrast, Western blot analysis revealed no difference in mPGES-2 levels between end-stage AD brain tissue and control brain tissue. These results suggest that in human cortex, mPGES-2 is constitutive in neurons and endothelium and induced in activated microglia. Furthermore, the high immunoreactivity of mPGES-2 in pyramidal neurons of AD brains indicates that it might have a potential role in the functional replacement of cytosolic PGES or inactive mPGES-1 in later stages of AD. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19664621      PMCID: PMC2864315          DOI: 10.1016/j.expneurol.2009.07.027

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  51 in total

1.  Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia.

Authors:  J M Schwab; T D Nguyen; E Postler; R Meyermann; H J Schluesener
Journal:  Acta Neuropathol       Date:  2000-06       Impact factor: 17.088

2.  Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid.

Authors:  Noel G Carlson
Journal:  J Neurosci Res       Date:  2003-01-01       Impact factor: 4.164

3.  Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury.

Authors:  Jan M Schwab; Rudi Beschorner; Richard Meyermann; Fatma Gözalan; Hermann J Schluesener
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

4.  Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain.

Authors:  Daniel Paris; Kirk P Townsend; Demian F Obregon; James Humphrey; Michael Mullan
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-09       Impact factor: 3.072

5.  Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons.

Authors:  A V Yermakova; J Rollins; L M Callahan; J Rogers; M K O'Banion
Journal:  J Neuropathol Exp Neurol       Date:  1999-11       Impact factor: 3.685

6.  Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.

Authors:  Zhongmin Xiang; Lap Ho; Shrishailam Yemul; Zhong Zhao; Wein Qing; Patrick Pompl; Kevin Kelley; Anju Dang; Weiping Qing; David Teplow; Giulio Maria Pasinetti
Journal:  Gene Expr       Date:  2002

7.  Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2.

Authors:  Makoto Murakami; Karin Nakashima; Daisuke Kamei; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Yoshihiro Ohmiya; Kikuko Watanabe; Ichiro Kudo
Journal:  J Biol Chem       Date:  2003-06-30       Impact factor: 5.157

8.  Apoptotic PC12 cells exposing phosphatidylserine promote the production of anti-inflammatory and neuroprotective molecules by microglial cells.

Authors:  Roberta De Simone; Maria Antonietta Ajmone-Cat; Paola Tirassa; Luisa Minghetti
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

9.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Authors:  Paul S Aisen; Kimberly A Schafer; Michael Grundman; Eric Pfeiffer; Mary Sano; Kenneth L Davis; Martin R Farlow; Shelia Jin; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2003-06-04       Impact factor: 56.272

10.  From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.

Authors:  Giulio Maria Pasinetti
Journal:  J Alzheimers Dis       Date:  2002-10       Impact factor: 4.472

View more
  13 in total

1.  Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.

Authors:  B Teter; T Morihara; G P Lim; T Chu; M R Jones; X Zuo; R M Paul; S A Frautschy; G M Cole
Journal:  Neurobiol Dis       Date:  2019-04-02       Impact factor: 5.996

2.  Microsomal prostaglandin E synthase type 2 (mPGES2) is a glutathione-dependent heme protein, and dithiothreitol dissociates the bound heme to produce active prostaglandin E2 synthase in vitro.

Authors:  Fusao Takusagawa
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

Review 3.  Role of prostaglandins in neuroinflammatory and neurodegenerative diseases.

Authors:  Isabel Vieira de Assis Lima; Leandro Francisco Silva Bastos; Marcelo Limborço-Filho; Bernd L Fiebich; Antonio Carlos Pinheiro de Oliveira
Journal:  Mediators Inflamm       Date:  2012-06-18       Impact factor: 4.711

4.  Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.

Authors:  Antonio C P de Oliveira; Eduardo Candelario-Jalil; Julia Langbein; Lena Wendeburg; Harsharan S Bhatia; Johannes C M Schlachetzki; Knut Biber; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2012-01-03       Impact factor: 8.322

5.  Low-dose aspirin (acetylsalicylate) prevents increases in brain PGE2, 15-epi-lipoxin A4 and 8-isoprostane concentrations in 9 month-old HIV-1 transgenic rats, a model for HIV-1 associated neurocognitive disorders.

Authors:  Helene C Blanchard; Ameer Y Taha; Stanley I Rapoport; Zhi-Xin Yuan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2015-01-13       Impact factor: 4.006

6.  Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice.

Authors:  Christian Griñán-Ferré; Sara Sarroca; Aleksandra Ivanova; Dolors Puigoriol-Illamola; Fernando Aguado; Antoni Camins; Coral Sanfeliu; Mercè Pallàs
Journal:  Aging (Albany NY)       Date:  2016-04       Impact factor: 5.682

7.  Prostaglandin E2 produced following infection with Theiler's virus promotes the pathogenesis of demyelinating disease.

Authors:  Seung Jae Kim; Young-Hee Jin; Byung S Kim
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

8.  Putative role of prostaglandin receptor in intracerebral hemorrhage.

Authors:  Shekher Mohan; Abdullah S Ahmad; Alexander V Glushakov; Chase Chambers; Sylvain Doré
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

9.  Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats.

Authors:  Yuanxin Guo; Wenjuan Lei; Jianfeng Wang; Xinyue Hu; Yuling Wei; Chaonan Ji; Junqing Yang
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 10.  Orphan proteins of unknown function in the mitochondrial intermembrane space proteome: New pathways and metabolic cross-talk.

Authors:  Esther Nuebel; Phanee Manganas; Kostas Tokatlidis
Journal:  Biochim Biophys Acta       Date:  2016-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.